WO2013062084A1 - Analysis device and analysis method - Google Patents

Analysis device and analysis method Download PDF

Info

Publication number
WO2013062084A1
WO2013062084A1 PCT/JP2012/077717 JP2012077717W WO2013062084A1 WO 2013062084 A1 WO2013062084 A1 WO 2013062084A1 JP 2012077717 W JP2012077717 W JP 2012077717W WO 2013062084 A1 WO2013062084 A1 WO 2013062084A1
Authority
WO
WIPO (PCT)
Prior art keywords
phase extraction
sample
solid phase
solid
drug
Prior art date
Application number
PCT/JP2012/077717
Other languages
French (fr)
Japanese (ja)
Inventor
伊藤 伸也
泉 和氣
Original Assignee
株式会社日立ハイテクノロジーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社日立ハイテクノロジーズ filed Critical 株式会社日立ハイテクノロジーズ
Publication of WO2013062084A1 publication Critical patent/WO2013062084A1/en

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40Concentrating samples
    • G01N1/405Concentrating samples by adsorption or absorption
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/02Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
    • G01N35/025Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations having a carousel or turntable for reaction cells or cuvettes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N2030/009Extraction
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/02Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
    • G01N35/04Details of the conveyor system
    • G01N2035/0439Rotary sample carriers, i.e. carousels
    • G01N2035/0441Rotary sample carriers, i.e. carousels for samples
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/02Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
    • G01N35/04Details of the conveyor system
    • G01N2035/0439Rotary sample carriers, i.e. carousels
    • G01N2035/0443Rotary sample carriers, i.e. carousels for reagents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/02Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
    • G01N35/04Details of the conveyor system
    • G01N2035/0439Rotary sample carriers, i.e. carousels
    • G01N2035/0444Rotary sample carriers, i.e. carousels for cuvettes or reaction vessels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/60Construction of the column
    • G01N30/6091Cartridges

Definitions

  • the present invention relates to an analysis apparatus and an analysis method.
  • Mass spectrometry is an analysis method that ionizes a measurement target component and measures it based on the mass of the generated ions.
  • An analysis method called MS / MS that performs mass analysis multiple times is a measurement target component ion.
  • MS mass spectrometry
  • pretreatments such as solid-phase extraction (Solid Phase Extraction, SPE) and liquid-liquid extraction (Liquid-Liquid Extraction, LLE) are used as means for increasing the degree of purification of the sample by LC-MS (or LC-MS / MS). It is done before the analysis.
  • a sample containing a major component with high viscosity and high concentration such as blood
  • pretreatment of a sample containing a main component having a high viscosity and a high concentration is essential.
  • Solid phase extraction is present in a sample solution by capturing a chemical substance to be measured by interaction on a surface of a fine particle having a particle diameter of several ⁇ m to several tens of ⁇ m called a solid phase extraction material. It is a method of separating and purifying from other substances.
  • liquid-liquid extraction is a method in which a sample solution is dispensed and stirred in two types of solvents that are not mixed with each other, such as water and hexane, and the measurement target is determined by the difference in distribution coefficient between the two types of solvents. This is a method for separating a substance from other substances.
  • solid-phase extraction SPE
  • SPE solid-phase extraction
  • LC-MS LC-MS / MS
  • pretreatment by solid-phase extraction (SPE) and LC-MS (or LC-MS / MS) can be automated.
  • solid phase extraction (SPE) is characterized in that the pretreatment time can be reduced by simultaneous processing of multiple samples using a 96-well microplate or the like.
  • solid phase extraction As a biological sample analysis using solid phase extraction (SPE) and LC-MS, for example, in Patent Document 1, biological samples such as serum and urine are processed off-line using a 96-well solid phase extraction plate and directly applied to MS. Quantification of amino acids, carnitines, sugars, immunosuppressants, and the like is performed by measuring by sample injection or LC-MS.
  • examples of the solid phase extraction cartridge used in offline processing include a 96-well plate described in Patent Document 1 and Patent Document 2, and a syringe container as described in Patent Document 3 and so on.
  • the solid phase extraction cartridge used by connecting online is the same as the precolumn of the liquid chromatography (LC) so as to withstand high pressure as described in Patent Document 4. There is something with the shape.
  • Patent Document 5 provides a method of using a solid phase extraction material filled in a pipette tip provided with a filter inside.
  • the type of drug to be measured varies depending on the sample, that is, the patient. Further, the concentration of the drug to be measured that is assumed to be present in the sample varies greatly depending on the type of drug. This is because the blood drug concentration (treatment area) where the therapeutic effect appears is different for each drug.
  • the therapeutic range is 50 to 100 ⁇ g / mL
  • the therapeutic range of tacrolimus used as an immunosuppressive agent is 2 to 20 ng / mL, which is 1000 times or more. There is a density difference.
  • the automatic analyzer is required to measure various types of drugs in a wide range of concentrations assumed for each drug. For this purpose, it is required to perform an optimal pretreatment for each sample. Specifically, it is desired to optimize the amount of the sample solution, the type and amount of the extract, and the type and amount of the solid phase extraction material for each measurement target. Moreover, when an automatic analyzer is actually used for clinical examinations such as hospitals, when a highly urgent patient sample is supplied to the device, it is required to preferentially measure the sample.
  • the pretreatment apparatus using the 96-well plate described in Patent Document 1 and Patent Document 2 can process a large amount of samples at one time, while a dispensing head equipped with multiple syringes is provided. Since there is only one, there is a problem that a multi-item extraction process using different types or different amounts of eluate cannot be performed. Further, in clinical examinations, there is a problem that it is difficult to secure a sufficient amount of sample in a 96-well plate for each processing operation. Furthermore, in the case of a pre-processing apparatus using a plate, after starting processing once, the next processing request sample cannot be started until the processing being executed is completed, and it is difficult to perform flexible processing. There is a problem.
  • the amount of the solid-phase extraction material can be changed for each sample by filling the pipette tip with the solid-phase extraction material slurry, but the solid-phase extraction material is prevented from dropping from the pipette tip. Therefore, it is necessary to use a viscous liquid such as glycerol as the slurry solvent. There is a problem in that this glycerol adsorbs on the surface of the extraction material, thereby affecting the solid-phase extraction efficiency of the drug.
  • the drug to be measured is a chemical substance with various physicochemical properties depending on its use, and it is technically difficult to prepare a highly viscous liquid that does not affect all the drugs. .
  • the present invention provides an analyzer and an analysis method for performing pretreatment under optimal conditions for each sample for samples containing drugs of various types and therapeutic areas when measuring drugs in the sample. Is an issue.
  • the present invention is an analyzer for measuring a drug contained in a measurement sample, and is a solid phase extraction material dispensing means for injecting a solid phase extraction material into a solid phase extraction container Pretreatment means for injecting the measurement sample into the solid phase extraction container into which the solid phase extraction material has been injected and generating an extraction sample liquid by solid extraction processing, and the drug in the extraction sample liquid And a measuring means for measuring.
  • the present invention when measuring a drug in a sample, pretreatment is performed on the sample containing various types and drugs in a therapeutic area under optimum conditions for each sample, and the measurement can be accurately performed in a mass spectrometer.
  • An analysis apparatus and an analysis method that can be performed can be provided.
  • FIG. 1 is a configuration diagram of an automatic analyzer 100 according to the first embodiment.
  • the automatic analyzer 100 is an analyzer that can automatically and continuously measure the concentration of a drug contained in a measurement sample.
  • an asthma drug theophylline drug in a serum sample (measurement sample) is used.
  • the automatic analyzer 100 includes a sample container 101, a sample setting unit 102, a sample information reading unit 103, a solid phase extraction cartridge (solid phase extraction container) 104, an extraction material liquid container 105, and an extraction material liquid dispensing mechanism.
  • the container installation unit 115, the consumable product installation unit 116, the sample introduction unit 117, the ion source 118, the mass analysis unit 119, and the control unit 120 are configured.
  • the sample container 101 stores a serum sample (measurement sample) to be measured.
  • the sample placement unit 102 is configured such that the sample container 101 is disposed and the position of the sample vessel 101 can be moved (rotated) by rotating the sample placement unit 102.
  • the sample information reading unit 103 can read the sample information written in the sample container 101.
  • the solid phase extraction cartridge 104 dispenses a sample during the solid phase extraction process.
  • the extraction material liquid container 105 stores the extraction material liquid.
  • the extraction material liquid dispensing mechanism 106 is capable of dispensing the extraction material liquid slurry stored in the extraction material liquid container 105 to the solid phase extraction cartridge 104.
  • the stirring mechanism 107 can form an extraction material liquid slurry by stirring the extraction material liquid in the extraction material liquid container 105.
  • the processing unit 108 can sequentially perform a solid phase extraction process using the solid phase extraction cartridge 104.
  • the reagent container 109 stores various reagents.
  • the reagent placement unit 110 is provided with a reagent container 109 such as a washing solution or an eluate used for the extraction process, and the reagent placement unit 110 can be rotated to move the position of the reagent container 109 (rotation movement). It has become.
  • the sample dispensing mechanism 111 is capable of dispensing a serum sample (measurement sample) stored in the sample container 101 to the solid phase extraction cartridge 104.
  • the reagent dispensing mechanism 112 is capable of dispensing the reagent stored in the reagent container 109 to the solid phase extraction cartridge 104.
  • the pressurizing mechanism 113 can pass the liquid in the solid phase extraction cartridge 104 downward by pressurization.
  • the extraction container 114 can collect the pretreated sample discharged from the solid phase extraction cartridge 104.
  • the extraction container installation unit 115 is configured such that the extraction container 114 is arranged, and the position of the extraction container 114 can be moved (rotated) by the rotation of the extraction container installation unit 115.
  • the consumables installation unit 116 is provided with consumables such as the solid phase extraction cartridge 104 and the extraction container 114.
  • the sample introduction unit 117 can dispense the extracted sample and send the solution to the ion source 118.
  • the ion source 118 is an electrospray ion source (ESI), and can ionize a sample that has been pretreated.
  • the mass analyzer 119 can perform mass analysis on the components of the sample ionized by the ion source 118.
  • the control unit 120 stores sample information and measurement condition information, which will be described later, and can control the operation of the automatic analyzer 100 using these information. In addition, the control unit 120 can collect and analyze the results measured by the mass analysis unit 119.
  • some functions of the ion source 118, the mass analyzer 119, and the controller 120 are measurement means for measuring the concentration of the drug in the preprocessed measurement sample, and the remaining components (Including a part of the function of the control unit 120) is a pretreatment means for performing a pretreatment including a solid phase extraction process on the measurement sample.
  • FIG. 2 is a chart showing steps of solid phase extraction pretreatment by the automatic analyzer 100 according to the first embodiment.
  • a serum sample (measurement sample) is dispensed and stored in the sample container 101 and set in the sample setting unit 102.
  • a bar code 121 in which information (sample information) related to the sample such as the specimen ID, the liquid property of the sample, and the drug to be measured is recorded is prepared in advance.
  • a code 121 is attached.
  • the automatic analyzer 100 measures the theophylline concentration in the serum sample in the following steps.
  • Step 1 Read sample information
  • the automatic analyzer 100 rotates the sample setting unit 102 in which the sample container 101 is set, and passes the sample container 101 in front of the sample information reading unit 103.
  • the sample information reading unit 103 reads sample information from the barcode 121 of the sample container 101 and sends the read information to the control unit 120.
  • the control unit 120 includes, for each sample type and drug, pretreatment conditions such as sample amount, type and amount of extraction material, solid-phase extraction conditions (such as type and amount of washing liquid and eluate, pressurization condition), and mass. Analysis (MS) measurement conditions are stored in advance as a database DB. When there are a plurality of sample types used for concentration analysis for a certain drug, a database is created for each sample type for that drug.
  • the control unit 120 calls the preprocessing conditions and mass spectrometry (MS) measurement conditions used for theophylline measurement from the sample information sent from the sample information reading unit 103 as device control parameters, and transmits them to each unit of the device.
  • pretreatment conditions such as sample amount, type and amount of extraction material, solid-phase extraction conditions (such as type and amount of washing liquid and eluate, pressurization condition), and mass. Analysis (MS) measurement conditions are stored in advance as a database DB.
  • MS mass spectrometry
  • the therapeutic range is 10 to 20 ⁇ g / mL
  • the automatic analyzer 100 needs to quantify in a concentration range of about 1 to 50 ⁇ g / mL including the therapeutic range.
  • This concentration range is a considerably high concentration range in view of detection sensitivity of mass spectrometry (MS) for theophylline, and therefore, a small amount of sample may be used, for example, about 20 ⁇ L is sufficient.
  • MS mass spectrometry
  • the extraction material liquid dispensing mechanism 106 dispenses a set amount of the extracted material liquid slurry from the extraction material liquid container 105 based on the device control parameter transmitted from the control unit 120, and supplies it to the solid phase extraction cartridge 104. inject.
  • the extraction material liquid is an organic solvent such as water or methanol containing a solid phase extraction material.
  • the solid phase extraction material for example, “NOBIAS RP-SG1” manufactured by Hitachi High-Technologies Corporation, which is a reverse phase solid phase extraction material, can be used. In this case, a 50% aqueous methanol solution is suitable as the solvent.
  • the ratio of the extraction material liquid slurry is suitably 1 mL of 50% methanol aqueous solution with respect to 20 mg of the solid phase extraction material.
  • the extraction material liquid slurry is sufficiently stirred before dispensing by the stirring mechanism 107 to form a uniform slurry of the solid phase extraction material.
  • a magnetic stirrer is simple.
  • a stirrer covered with a Teflon (registered trademark) resin or the like with a bar magnet is put into a substance to be stirred (in this case, an extractant liquid slurry), and installed in the lower part of the extractant liquid container 105.
  • the magnet inside the stirring mechanism 107 is rotated by a motor.
  • the solid phase extraction cartridge 104 into which the extraction material liquid slurry has been injected is pressurized from above by the pressurizing mechanism 113, and the solvent passes downward.
  • FIG. 4 is a cross-sectional view showing the structure of the solid phase extraction cartridge 104.
  • a filter 122 is installed below the inside of the solid-phase extraction cartridge 104.
  • the hole diameter of the filter 122 is 10 ⁇ m. According to such a structure, the solvent pressurized by the pressurizing mechanism 113 passes through the solid phase extraction cartridge 104, while the solid phase extraction material remains on the filter 122.
  • Step 4 Equilibration
  • pure water arranged in the reagent arrangement unit 110 is dispensed by the reagent dispensing mechanism 112 to the solid phase extraction cartridge 104 after passing through the solvent.
  • the injected pure water is pressurized by the pressurizing mechanism 113 and passes below the solid phase extraction cartridge 104.
  • the preparation for sample processing is completed by the steps so far.
  • Step 5 Sample injection
  • the reagent dispensing mechanism 112 dispenses a theophylline internal standard substance (theophylline-d6) solution from the reagent placement unit 110 and injects it into the solid phase extraction cartridge 104 in which the solid phase extraction material has been injected and the sample processing preparation has been completed.
  • the sample dispensing mechanism 111 dispenses a serum sample (measurement sample) from the sample container 101 and injects it into the solid phase extraction cartridge 104 into which the internal standard substance has been injected.
  • the serum sample and the internal standard substance liquid injected into the solid phase extraction cartridge 104 are pressurized from above by the pressurizing mechanism 113, pass through the solid phase extraction material, and discharged downward.
  • theophylline (drug) and the internal standard substance contained in the serum sample are selectively adsorbed on the surface of the solid-phase extraction material by hydrophobic interaction.
  • Step 6 Washing
  • the reagent dispensing mechanism 112 dispenses 200 ⁇ L of pure water as a cleaning liquid stored in the reagent container 109.
  • the solid-phase extraction cartridge 104 is washed by performing a pressure treatment by the pressure mechanism 113.
  • components in the serum sample remaining nonspecifically on the surface of the solid-phase extraction material are discharged.
  • Step 7 After washing, the reagent dispensing mechanism 112 dispenses 100 ⁇ L of 50% methanol aqueous solution as an eluent into the solid phase extraction cartridge 104.
  • the extraction sample solution in which theophylline (drug) and theophylline-d6 (internal standard substance) are eluted from the solid-phase extraction cartridge 104 is collected in the extraction container 114 by performing a pressurizing process with the pressurizing mechanism 113.
  • the automatic analyzer 100 moves the extraction container 114 from which the extraction sample solution has been collected to the position of the sample introduction unit 117 by the rotation of the extraction container installation unit 115.
  • the extracted sample solution is introduced into the ion source 118 by the sample introduction unit 117.
  • Theophylline (drug) and theophylline-d6 are ionized by the ion source 118, and both components are detected by the mass spectrometer 119.
  • the detected signal strengths of both components are transferred to the control unit 120.
  • the control unit 120 calculates the theophylline concentration in the serum sample from the transferred signal intensity ratio of both components and the signal intensity ratio of the calibrator obtained in advance.
  • the automatic analyzer 100 measures the theophylline concentration in the serum sample.
  • the pretreatment conditions corresponding to the types of each drug and the sample to be measured are stored in a database, and according to the values of the database. Pretreatment including solid phase extraction is performed. As a result, it is possible to always select the optimal amount of solid phase extraction material, sample, and various reagents, to suppress unnecessary reagent consumption and to reduce the running cost for analysis processing.
  • FIG. 5 is a configuration diagram of an automatic analyzer 500 according to the second embodiment.
  • the automatic analyzer 500 according to the second embodiment is different from the automatic analyzer 100 according to the first embodiment in that a stirring mechanism 123 that stirs the inside of the container with respect to the solid phase extraction cartridge 104 is provided.
  • a stirring mechanism 123 for example, an ultrasonic stirrer can be used.
  • the contact rate between the sample in the solid-phase extraction cartridge 104 and a reagent such as a solid-phase extraction material can be improved.
  • the concentration of the measurement target substance (drug) in the measurement sample can be increased. Even if it is low, it is possible to measure accurately.
  • the automatic analyzer 500 is an analyzer that can automatically and continuously measure the concentration of a drug contained in a measurement sample.
  • the immunosuppressant tacrolimus (drug) contained in a whole blood sample is used. It is assumed that the concentration is analyzed. Since tacrolimus in the whole blood sample is present in blood cell components, solid phase extraction cannot be performed as it is.
  • aqueous zinc solution By adding 150 ⁇ L of aqueous zinc solution and 200 ⁇ L of methanol solution, blood cells are destroyed and precipitates are formed, and the supernatant after centrifugation is used as a whole blood treatment liquid sample (measurement sample).
  • ascomycin is used at the time of mass spectrometry (MS) measurement as an internal standard substance of tacrolimus.
  • the solid phase extraction process is performed in a batch manner in the pretreatment.
  • the batch type refers to a system in which solid phase extraction is performed with the drug in the measurement sample by freely moving the measurement sample solution without fixing the solid phase extraction material to a part of the cartridge.
  • FIG. 6 is a chart showing steps of solid phase extraction pretreatment by the automatic analyzer 500 according to the second embodiment.
  • a whole blood processing solution sample (measurement sample) is dispensed and stored in the sample container 101, set in the sample setting unit 102, and a barcode 121 in which sample information is recorded (see FIG. 3) ) Is attached to the side surface of the sample container 101.
  • Step 1 Read sample information
  • Step 1 Reading sample information
  • the control unit 120 calls the preprocessing conditions and mass spectrometry (MS) measurement conditions used for tacrolimus measurement as device control parameters from the sample information sent from the sample information reading unit 103, and transmits them to each unit of the device.
  • MS mass spectrometry
  • the therapeutic range is 2 to 20 ng / mL
  • the automatic analyzer 500 is required to perform quantification in a concentration range of about 0.5 to 30 ng / mL including the therapeutic range.
  • tacrolimus in whole blood has a lower concentration than, for example, theophylline mentioned in the first embodiment, and a sample amount of 200 ⁇ L is required for accurate measurement by the automatic analyzer 500.
  • parameters relating to the amount of the solid-phase extraction material optimized for the measurement of tacrolimus in the assumed concentration range, the washing liquid, the eluate, etc. are called and transmitted to each part of the apparatus.
  • the extraction material liquid dispensing mechanism 106 is set based on the apparatus control parameter transmitted from the control unit 120. A certain amount of extraction material liquid slurry is dispensed from the extraction material liquid container 105 and injected into the solid phase extraction cartridge 104. The solid-phase extraction cartridge 104 into which the extraction material liquid slurry has been injected is pressurized from above by the pressurizing mechanism 113, and the solvent passes downward.
  • Step 5A Sample injection
  • the sample dispensing mechanism 111 dispenses the whole blood processing liquid sample (measurement sample) from the sample container 101 and injects it into the solid phase extraction cartridge 104 into which the solid phase extraction material has been injected.
  • Step 5B stirring
  • the automatic analyzer 100 rotates the processing unit 108 to move the solid-phase extraction cartridge 104 into which the solid-phase extraction material and the whole blood processing liquid sample (measurement sample) are dispensed to the position of the stirring mechanism 123, thereby Stir the phase extraction material and the whole blood treatment liquid sample.
  • the solid phase extraction material, tacrolimus in the sample solution and the internal standard ascomycin can be brought into contact with each other a sufficient number of times, and are adsorbed on the solid phase extraction material.
  • the automatic analyzer 100 rotates the processing unit 108 to move the solid-phase extraction cartridge 104 that has been sufficiently stirred to the position of the pressurizing mechanism 113.
  • the whole blood processing liquid sample in the solid-phase extraction cartridge 104 passes downward by the pressurizing process of the pressurizing mechanism 113.
  • tacrolimus and ascomycin remain adsorbed on the solid phase extraction material, and remain on the upper part of the filter 122 in the cartridge together with the solid phase extraction material.
  • Step 6 Washing
  • the reagent dispensing mechanism 112 dispenses 200 ⁇ L of pure water as a washing liquid stored in the reagent container 109.
  • the solid-phase extraction cartridge 104 is washed by performing a pressure treatment by the pressure mechanism 113.
  • the components in the whole blood processing liquid sample remaining non-specifically on the surface of the solid-phase extraction material are discharged.
  • Step 7 Elution
  • the reagent dispensing mechanism 112 dispenses 50 ⁇ L of methanol as an eluent to the solid phase extraction cartridge 104.
  • the extraction sample solution in which tacrolimus (drug) and ascomycin (internal standard substance) are eluted from the solid-phase extraction cartridge 104 is recovered in the extraction container 114 by performing a pressurizing process by the pressurizing mechanism 113.
  • the automatic analyzer 500 moves the extraction container 114 from which the extraction sample solution has been collected to the position of the sample introduction unit 117 by the rotation of the extraction container installation unit 115.
  • the extracted sample solution is introduced into the ion source 118 by the sample introduction unit 117.
  • Tacrolimus (drug) and ascomycin (internal standard substance) are ionized by the ion source 118, and both components are detected by the mass spectrometer 119.
  • the detected signal strengths of both components are transferred to the control unit 120.
  • the control unit 120 calculates the tacrolimus concentration in the whole blood sample from the transferred signal intensity ratio of both components and the signal intensity ratio of the calibrator obtained in advance. In the process as described above, the automatic analyzer 500 measures the tacrolimus concentration in the whole blood sample.
  • the automatic analyzer 500 in addition to the same effects as those of the automatic analyzer 100 according to the first embodiment, it is possible to accurately measure even when the concentration of the measurement target substance in the sample is low. it can.
  • the automatic analyzer according to the present embodiment is not limited to the configuration of the above-described embodiment, and various modifications can be made without departing from the spirit of the invention.
  • the measurement using a single solid phase extraction material has been described, but it is also possible to supply a plurality of solid phase extraction materials to one solid phase extraction cartridge.
  • a plurality of extraction material liquid containers 105 each containing different types of solid phase extraction materials are arranged on the operation line of the extraction material liquid dispensing mechanism 106, and a plurality of (Step 3: extraction material liquid slurry injection) are arranged. It can be realized by repeating it.
  • Such a method is effective, for example, when measuring a drug whose solid-phase extraction efficiency is improved by mixing a cation exchange solid-phase extraction material having a sulfonic acid group and a reverse-phase solid-phase extraction material. .
  • it is necessary to optimize the pH of the washing solution or the eluate and to change the type and amount of the eluate, but these changes are easy if the automatic analyzers 100 and 500 are used.
  • the mass spectrometer 119 of the automatic analyzers 100 and 500 has been described as performing quantitative analysis for measuring the concentration of a drug in the extracted sample solution, the present invention is not limited to this, and the extracted sample solution is not limited thereto.
  • a qualitative analysis for identifying the substance of the drug in the drug may be performed, or a qualitative analysis and a quantitative analysis may be performed simultaneously.
  • the analyzer according to the present invention is effective as an analyzer for measuring the concentration of a drug contained in a measurement sample, and particularly using a mass spectrometer such as an LC-MS (or LC-MS / MS) analyzer. It is suitable for an analyzer that measures the concentration of a drug contained in a biological sample.

Landscapes

  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

The present invention provides an analysis device and an analysis method with which samples containing drugs of different kinds and for various therapeutic ranges are subjected to a pretreatment under optimum conditions when the drug in the sample is measured. An analysis device (100) for measuring a drug contained in a measurement sample is provided with: an extract liquid injection mechanism (106) for injecting a solid-phase extract into a solid-phase extract cartridge (104); a pretreatment means for injecting a measurement sample into the solid-phase extract cartridge (104) into which the solid-phase extract has been injected, and generating an extract sample liquid by means of a solid extraction treatment; and a measurement means for measuring the drug in the extract sample liquid.

Description

分析装置および分析方法Analysis apparatus and analysis method
 本発明は、分析装置および分析方法に関する。 The present invention relates to an analysis apparatus and an analysis method.
 従来、血液や尿、細胞抽出液などの生体試料をはじめとした複雑な組成を有する液体試料中に微量に存在する化学物質の測定が行われている。このような測定の方法として、液体クロマトグラフィ(Liquid Chromatography,LC)やキャピラリ電気泳動(Capillary Electrophoresis,CE)などの高い分離性能を有する分離手段と、質量分析法(Mass Spectrometry,MS)や紫外可視吸光光度法(Ultraviolet-Visible Spectrophotometry,UV)などの検出器を組み合わせた分析法が、多くの分野で用いられている。 Conventionally, measurement of chemical substances present in minute amounts in liquid samples having a complicated composition such as biological samples such as blood, urine, and cell extracts has been performed. Such measurement methods include high-separation means such as liquid chromatography (Liquid Chromatography, LC) and capillary electrophoresis (Capillary Electrophoresis, CE), mass spectrometry (Mass Spectrometry, MS), and UV-visible absorption. Analytical methods combining detectors such as photometric methods (Ultraviolet-Visible-Spectrophotometry, UV) are used in many fields.
 質量分析(MS)は、測定対象成分をイオン化し、生成したイオンの質量に基づいて測定する分析法であり、質量分析を複数回実施するMS/MSと呼ばれる分析法は、測定対象成分イオンをフラグメント化することにより、試料溶液中の微量成分を高感度かつ高選択性をもって検出できる。液体クロマトグラフィ(LC)と質量分析(MS)をオンラインで接続したLC-MS(またはLC-MS/MS)は、液体試料中の微量物質分析に汎用されている。 Mass spectrometry (MS) is an analysis method that ionizes a measurement target component and measures it based on the mass of the generated ions. An analysis method called MS / MS that performs mass analysis multiple times is a measurement target component ion. By fragmenting, a trace component in the sample solution can be detected with high sensitivity and high selectivity. LC-MS (or LC-MS / MS) in which liquid chromatography (LC) and mass spectrometry (MS) are connected on-line is widely used for analysis of trace substances in liquid samples.
 また、試料の精製度を高める手段として、固相抽出(Solid Phase Extraction,SPE)や液液抽出(Liquid-Liquid Extraction,LLE)などの前処理を、LC-MS(またはLC-MS/MS)分析の前に実施することが行われている。特に、血液のように高粘度かつ高濃度の主要成分を含む試料について、前処理を行わずに直接LC-MSに注入すると、装置の汚染による測定精度低下を引き起こすのみならず、流路詰まりによって測定が行えなくなってしまう可能性がある。このため、高粘度かつ高濃度の主要成分を含む試料の前処理は必須となる。 In addition, pretreatments such as solid-phase extraction (Solid Phase Extraction, SPE) and liquid-liquid extraction (Liquid-Liquid Extraction, LLE) are used as means for increasing the degree of purification of the sample by LC-MS (or LC-MS / MS). It is done before the analysis. In particular, if a sample containing a major component with high viscosity and high concentration, such as blood, is injected directly into the LC-MS without pretreatment, not only will the measurement accuracy be reduced due to contamination of the device, but also due to clogging of the flow path. Measurement may not be possible. For this reason, pretreatment of a sample containing a main component having a high viscosity and a high concentration is essential.
 固相抽出(SPE)とは、固相抽出材と呼ばれる粒子径数μmから数十μmの微粒子に表面に、測定対象である化学物質を相互作用により捕捉させることで、試料溶液中に存在する他の物質と分離精製する方法である。また、液液抽出(LLE)とは、水とヘキサンのように互いに混ざり合わない2種の溶媒に、試料溶液を分注および攪拌して、2種の溶媒に対する分配係数の違いによって測定対象の物質と他の物質を分離する方法である。
 特に、固相抽出(SPE)は、LC-MS(またはLC-MS/MS)とのオンライン接続が容易なため、固相抽出(SPE)による前処理とLC-MS(またはLC-MS/MS)による測定の自動化を行うことができる。また、固相抽出(SPE)は、96穴マイクロプレートなどを用いた多試料の同時処理による前処理時間の短縮が可能となる、などの特徴を有する。
Solid phase extraction (SPE) is present in a sample solution by capturing a chemical substance to be measured by interaction on a surface of a fine particle having a particle diameter of several μm to several tens of μm called a solid phase extraction material. It is a method of separating and purifying from other substances. In addition, liquid-liquid extraction (LLE) is a method in which a sample solution is dispensed and stirred in two types of solvents that are not mixed with each other, such as water and hexane, and the measurement target is determined by the difference in distribution coefficient between the two types of solvents. This is a method for separating a substance from other substances.
In particular, since solid-phase extraction (SPE) is easy to connect online with LC-MS (or LC-MS / MS), pretreatment by solid-phase extraction (SPE) and LC-MS (or LC-MS / MS) ) Can be automated. In addition, solid phase extraction (SPE) is characterized in that the pretreatment time can be reduced by simultaneous processing of multiple samples using a 96-well microplate or the like.
 固相抽出(SPE)とLC-MSを用いた生体試料分析として、例えば特許文献1では、血清や尿などの生体試料を96穴の固相抽出プレートを用いてオフラインで処理し、直接MSに試料注入あるいはLC-MSで測定することにより、アミノ酸、カルニチン類、糖および免疫抑制剤などの定量を行っている。固相抽出(SPE)において、オフライン処理で用いられる固相抽出カートリッジとしては、例えば特許文献1や特許文献2に記載されている96穴プレートや、特許文献3に記載されているようなシリンジ容器などがある。また、固相抽出(SPE)において、オンライン接続して使用される固相抽出カートリッジとしては、特許文献4に記載されているように、高圧に耐えうるように液体クロマトグラフィ(LC)のプレカラムと同様の形状をしたものがある。 As a biological sample analysis using solid phase extraction (SPE) and LC-MS, for example, in Patent Document 1, biological samples such as serum and urine are processed off-line using a 96-well solid phase extraction plate and directly applied to MS. Quantification of amino acids, carnitines, sugars, immunosuppressants, and the like is performed by measuring by sample injection or LC-MS. In solid phase extraction (SPE), examples of the solid phase extraction cartridge used in offline processing include a 96-well plate described in Patent Document 1 and Patent Document 2, and a syringe container as described in Patent Document 3 and so on. Further, in the solid phase extraction (SPE), the solid phase extraction cartridge used by connecting online is the same as the precolumn of the liquid chromatography (LC) so as to withstand high pressure as described in Patent Document 4. There is something with the shape.
 特許文献1から特許文献4に挙げられたいずれのカートリッジにおいても、固相抽出材はフィルタを介してカートリッジ内に封入された状態で供給される。また、カートリッジに封入されずに測定時に固相抽出カートリッジを形成する手段として、特許文献5では内部にフィルタを備えたピペット先端に固相抽出材を充填して使用する方法を提供している。 In any of the cartridges listed in Patent Document 1 to Patent Document 4, the solid phase extraction material is supplied in a state of being enclosed in the cartridge through a filter. As a means for forming a solid phase extraction cartridge at the time of measurement without being enclosed in a cartridge, Patent Document 5 provides a method of using a solid phase extraction material filled in a pipette tip provided with a filter inside.
米国特許出願公開第2007/0004044号明細書US Patent Application Publication No. 2007/0004044 米国特許第6723236号明細書US Pat. No. 6,723,236 特開2002-316002号公報JP 2002-316002 A 欧州特許第1159597号明細書European Patent No. 11559597 米国特許第6770246号明細書US Pat. No. 6,770,246
 血液中の薬物濃度を測定する自動分析装置において、測定対象となる薬物の種類は、試料すなわち患者ごとに異なる。また、試料中に存在すると想定される測定対象薬物濃度は、薬物の種類ごとに大きく異なる。これは、治療効果が現れる血中薬物濃度(治療域)が薬物ごとに異なるためである。一例として、抗てんかん剤として使用されるバルプロ酸ナトリウムの場合、治療域は50~100μg/mLであり、免疫抑制剤として使用されるタクロリムスの治療域は2~20ng/mLと、1000倍以上の濃度差がある。 In the automatic analyzer that measures the drug concentration in the blood, the type of drug to be measured varies depending on the sample, that is, the patient. Further, the concentration of the drug to be measured that is assumed to be present in the sample varies greatly depending on the type of drug. This is because the blood drug concentration (treatment area) where the therapeutic effect appears is different for each drug. As an example, in the case of sodium valproate used as an antiepileptic agent, the therapeutic range is 50 to 100 μg / mL, and the therapeutic range of tacrolimus used as an immunosuppressive agent is 2 to 20 ng / mL, which is 1000 times or more. There is a density difference.
 すなわち、自動分析装置では、様々な種類の薬物を、各薬物ごとに想定される広範囲な濃度域において測定することが求められる。そのためには、試料ごとに最適な前処理を施すことが要求される。具体的には、試料液量、抽出液の種類および量、固相抽出材の種類および量を、測定対象ごとにそれぞれ最適化することが望まれる。また、実際に病院などの臨床検査に自動分析装置を使用する場合、緊急性の高い患者試料が装置に供給されると、その試料を優先して測定することが要求される。 That is, the automatic analyzer is required to measure various types of drugs in a wide range of concentrations assumed for each drug. For this purpose, it is required to perform an optimal pretreatment for each sample. Specifically, it is desired to optimize the amount of the sample solution, the type and amount of the extract, and the type and amount of the solid phase extraction material for each measurement target. Moreover, when an automatic analyzer is actually used for clinical examinations such as hospitals, when a highly urgent patient sample is supplied to the device, it is required to preferentially measure the sample.
 これらの要求に対して、特許文献1および特許文献2に記載された96穴プレートを用いた前処理装置では、多量の試料を一括処理可能である一方、多連シリンジを備えた分注ヘッドが1つしか配置されておらず、異なる種類あるいは異なる液量の溶出液を用いる多項目の抽出処理を行うことができないという問題点がある。また、臨床検査においては96穴プレートに十分な量の試料を処理動作ごとに確保するのは困難であるという問題点がある。さらに、プレートを用いた前処理装置の場合、一度処理を開始した後、次の処理依頼サンプルは、実行中の処理が終了するまで開始できず、臨機応変な処理をすることが困難であるという問題点がある。 In response to these requirements, the pretreatment apparatus using the 96-well plate described in Patent Document 1 and Patent Document 2 can process a large amount of samples at one time, while a dispensing head equipped with multiple syringes is provided. Since there is only one, there is a problem that a multi-item extraction process using different types or different amounts of eluate cannot be performed. Further, in clinical examinations, there is a problem that it is difficult to secure a sufficient amount of sample in a 96-well plate for each processing operation. Furthermore, in the case of a pre-processing apparatus using a plate, after starting processing once, the next processing request sample cannot be started until the processing being executed is completed, and it is difficult to perform flexible processing. There is a problem.
 特許文献3に記載されたシリンジ型固相抽出カラムや、特許文献4に記載されたカートリッジ型カラムでは、固相抽出材の量を変更する場合、変更したい数だけカラムを装置にあらかじめ準備する必要がある。このため、装置の消耗品コストが上昇するだけでなく、複数種類のカラムを試料ごとに選択する機構も必要となり、装置が複雑かつ大型化するという問題点がある。 In the syringe-type solid phase extraction column described in Patent Document 3 and the cartridge-type column described in Patent Document 4, when changing the amount of the solid-phase extraction material, it is necessary to prepare as many columns in the apparatus as desired in advance. There is. For this reason, not only the cost of the consumables of the apparatus rises, but also a mechanism for selecting a plurality of types of columns for each sample is required, and there is a problem that the apparatus becomes complicated and large.
 特許文献5に記載の方法では、ピペット先端に固相抽出材スラリを充填することで、試料ごとに固相抽出材の量を変更可能であるが、ピペット先端から固相抽出材の落下を防止するために、スラリ溶媒にグリセロールなど粘性のある液体を使用する必要がある。このグリセロールが抽出材表面に吸着することによって、薬物の固相抽出効率に影響を与えてしまうという問題点がある。特に、測定対象となる薬物は、その用途により様々な物理化学的性質をもつ化学物質であり、その全ての薬物に対して影響を与えない高粘性液体を準備することは技術的に困難である。また、検出器に質量分析装置を用いた場合、グリセロールのような粘性のある液体をイオン源に導入すると、イオン化効率の低下による信号強度の低下や信号のばらつきを引き起こすという問題点がある。 In the method described in Patent Document 5, the amount of the solid-phase extraction material can be changed for each sample by filling the pipette tip with the solid-phase extraction material slurry, but the solid-phase extraction material is prevented from dropping from the pipette tip. Therefore, it is necessary to use a viscous liquid such as glycerol as the slurry solvent. There is a problem in that this glycerol adsorbs on the surface of the extraction material, thereby affecting the solid-phase extraction efficiency of the drug. In particular, the drug to be measured is a chemical substance with various physicochemical properties depending on its use, and it is technically difficult to prepare a highly viscous liquid that does not affect all the drugs. . In addition, when a mass spectrometer is used as a detector, if a viscous liquid such as glycerol is introduced into the ion source, there is a problem in that the signal intensity decreases and the signal varies due to a decrease in ionization efficiency.
 そこで、本発明は、試料中の薬物を測定する際に、様々な種類や治療域の薬物を含む試料に対して試料ごとに最適な条件で前処理を行う分析装置および分析方法を提供することを課題とする。 Therefore, the present invention provides an analyzer and an analysis method for performing pretreatment under optimal conditions for each sample for samples containing drugs of various types and therapeutic areas when measuring drugs in the sample. Is an issue.
 このような課題を解決するために、本発明は、測定試料に含まれる薬物を測定する分析装置であって、固相抽出用容器内に固相抽出材を注入する固相抽出材分注手段と、前記固相抽出材が注入された前記固相抽出用容器内に前記測定試料を注入して固体抽出処理により抽出試料液を生成する前処理手段と、前記抽出試料液中の前記薬物を測定する測定手段と、を備えることを特徴とする分析装置である。 In order to solve such a problem, the present invention is an analyzer for measuring a drug contained in a measurement sample, and is a solid phase extraction material dispensing means for injecting a solid phase extraction material into a solid phase extraction container Pretreatment means for injecting the measurement sample into the solid phase extraction container into which the solid phase extraction material has been injected and generating an extraction sample liquid by solid extraction processing, and the drug in the extraction sample liquid And a measuring means for measuring.
 本発明によれば、試料中の薬物を測定する際に、様々な種類や治療域の薬物を含む試料に対して試料ごとに最適な条件で前処理を行い、質量分析装置において精度よく測定を行うことができる分析装置および分析方法を提供することができる。 According to the present invention, when measuring a drug in a sample, pretreatment is performed on the sample containing various types and drugs in a therapeutic area under optimum conditions for each sample, and the measurement can be accurately performed in a mass spectrometer. An analysis apparatus and an analysis method that can be performed can be provided.
第1実施形態に係る自動分析装置の構成図である。It is a block diagram of the automatic analyzer which concerns on 1st Embodiment. 第1実施形態に係る自動分析装置による固相抽出前処理の工程を示すチャートである。It is a chart which shows the process of the solid-phase extraction pretreatment by the automatic analyzer concerning a 1st embodiment. 試料容器に対する試料情報の付加方法の一例を示す説明図である。It is explanatory drawing which shows an example of the addition method of the sample information with respect to a sample container. 固相抽出カートリッジの構造を示す断面図である。It is sectional drawing which shows the structure of a solid-phase extraction cartridge. 第2実施形態に係る自動分析装置の構成図である。It is a block diagram of the automatic analyzer which concerns on 2nd Embodiment. 第2実施形態に係る自動分析装置による固相抽出前処理の工程を示すチャートである。It is a chart which shows the process of the solid phase extraction pretreatment by the automatic analyzer concerning a 2nd embodiment.
 以下、本発明を実施するための形態(以下「実施形態」という)について、適宜図面を参照しながら詳細に説明する。なお、各図において、共通する部分には同一の符号を付し重複した説明を省略する。 Hereinafter, modes for carrying out the present invention (hereinafter referred to as “embodiments”) will be described in detail with reference to the drawings as appropriate. In each figure, common portions are denoted by the same reference numerals, and redundant description is omitted.
≪第1実施形態≫
<自動分析装置100の構成>
 図1は、第1実施形態に係る自動分析装置100の構成図である。
 自動分析装置100は、測定試料に含まれる薬物の濃度を自動で連続的に測定することができる分析装置であり、第1実施形態では血清試料(測定試料)中に含まれる喘息薬テオフィリン(薬物)の濃度を分析するものとして説明する。
 自動分析装置100は、試料容器101と、試料設置部102と、試料情報読み取り部103と、固相抽出カートリッジ(固相抽出容器)104と、抽出材液容器105と、抽出材液分注機構106と、攪拌機構107と、処理部108と、試薬容器109と、試薬配置部110と、試料分注機構111と、試薬分注機構112と、加圧機構113と、抽出容器114と、抽出容器設置部115と、消耗品設置部116と、試料導入部117と、イオン源118と、質量分析部119と、制御部120と、によって構成される。
<< First Embodiment >>
<Configuration of automatic analyzer 100>
FIG. 1 is a configuration diagram of an automatic analyzer 100 according to the first embodiment.
The automatic analyzer 100 is an analyzer that can automatically and continuously measure the concentration of a drug contained in a measurement sample. In the first embodiment, an asthma drug theophylline (drug in a serum sample (measurement sample) is used. ) Is analyzed for analysis.
The automatic analyzer 100 includes a sample container 101, a sample setting unit 102, a sample information reading unit 103, a solid phase extraction cartridge (solid phase extraction container) 104, an extraction material liquid container 105, and an extraction material liquid dispensing mechanism. 106, stirring mechanism 107, processing unit 108, reagent container 109, reagent placement unit 110, sample dispensing mechanism 111, reagent dispensing mechanism 112, pressurization mechanism 113, extraction container 114, and extraction The container installation unit 115, the consumable product installation unit 116, the sample introduction unit 117, the ion source 118, the mass analysis unit 119, and the control unit 120 are configured.
 試料容器101は、測定対象となる血清試料(測定試料)が格納されている。試料設置部102は、試料容器101が配置され、試料設置部102が回転することにより試料容器101の位置を移動(回転移動)させることができるようになっている。試料情報読み取り部103は、試料容器101に記載された試料情報を読み取ることができるようになっている。固相抽出カートリッジ104は、固相抽出処理の際に試料が分注される。抽出材液容器105は、抽出材液が格納されている。抽出材液分注機構106は、抽出材液容器105に格納された抽出材液スラリを固相抽出カートリッジ104に分注することができるようになっている。攪拌機構107は、抽出材液容器105内の抽出材液を攪拌することによって抽出材液スラリを形成することができるようになっている。処理部108は、固相抽出カートリッジ104を用いて順次固相抽出処理を行うことができるようになっている。試薬容器109は、各種試薬が格納されている。試薬配置部110は、抽出処理に使用する洗浄液や溶出液等の試薬容器109が配置され、試薬配置部110が回転することにより試薬容器109の位置を移動(回転移動)させることができるようになっている。試料分注機構111は、試料容器101に格納された血清試料(測定試料)を固相抽出カートリッジ104に分注することができるようになっている。試薬分注機構112は、試薬容器109に格納された試薬を固相抽出カートリッジ104に分注することができるようになっている。 The sample container 101 stores a serum sample (measurement sample) to be measured. The sample placement unit 102 is configured such that the sample container 101 is disposed and the position of the sample vessel 101 can be moved (rotated) by rotating the sample placement unit 102. The sample information reading unit 103 can read the sample information written in the sample container 101. The solid phase extraction cartridge 104 dispenses a sample during the solid phase extraction process. The extraction material liquid container 105 stores the extraction material liquid. The extraction material liquid dispensing mechanism 106 is capable of dispensing the extraction material liquid slurry stored in the extraction material liquid container 105 to the solid phase extraction cartridge 104. The stirring mechanism 107 can form an extraction material liquid slurry by stirring the extraction material liquid in the extraction material liquid container 105. The processing unit 108 can sequentially perform a solid phase extraction process using the solid phase extraction cartridge 104. The reagent container 109 stores various reagents. The reagent placement unit 110 is provided with a reagent container 109 such as a washing solution or an eluate used for the extraction process, and the reagent placement unit 110 can be rotated to move the position of the reagent container 109 (rotation movement). It has become. The sample dispensing mechanism 111 is capable of dispensing a serum sample (measurement sample) stored in the sample container 101 to the solid phase extraction cartridge 104. The reagent dispensing mechanism 112 is capable of dispensing the reagent stored in the reagent container 109 to the solid phase extraction cartridge 104.
 加圧機構113は、加圧によって固相抽出カートリッジ104内の液を下方に通過させることができるようになっている。抽出容器114は、固相抽出カートリッジ104から排出される前処理済みの試料を回収することができるようになっている。抽出容器設置部115は、抽出容器114が配置され、抽出容器設置部115が回転することにより抽出容器114の位置を移動(回転移動)させることができるようになっている。消耗品設置部116は、固相抽出カートリッジ104および抽出容器114などの消耗品が設置されている。試料導入部117は、抽出試料の分注とイオン源118への送液を行うことができるようになっている。イオン源118は、エレクトロスプレイオン源(Electrospray Ionization,ESI)であり、前処理が終了した試料をイオン化することができるようになっている。質量分析部119は、イオン源118でイオン化された試料の成分を質量分析することができるようになっている。
 制御部120は、後述する試料情報や測定条件情報が格納されるとともに、これらの情報を用いて自動分析装置100の動作を制御することができるようになっている。また、制御部120は、質量分析部119で測定された結果の収集と解析を行うことができるようになっている。
The pressurizing mechanism 113 can pass the liquid in the solid phase extraction cartridge 104 downward by pressurization. The extraction container 114 can collect the pretreated sample discharged from the solid phase extraction cartridge 104. The extraction container installation unit 115 is configured such that the extraction container 114 is arranged, and the position of the extraction container 114 can be moved (rotated) by the rotation of the extraction container installation unit 115. The consumables installation unit 116 is provided with consumables such as the solid phase extraction cartridge 104 and the extraction container 114. The sample introduction unit 117 can dispense the extracted sample and send the solution to the ion source 118. The ion source 118 is an electrospray ion source (ESI), and can ionize a sample that has been pretreated. The mass analyzer 119 can perform mass analysis on the components of the sample ionized by the ion source 118.
The control unit 120 stores sample information and measurement condition information, which will be described later, and can control the operation of the automatic analyzer 100 using these information. In addition, the control unit 120 can collect and analyze the results measured by the mass analysis unit 119.
 自動分析装置100の構成のうち、イオン源118、質量分析部119および制御部120の一部機能が、前処理された測定試料中の薬物の濃度を測定する測定手段であり、残りの構成部(制御部120の一部機能を含む)が、測定試料に対して固相抽出処理を含む前処理を行う前処理手段となる。 Among the components of the automatic analyzer 100, some functions of the ion source 118, the mass analyzer 119, and the controller 120 are measurement means for measuring the concentration of the drug in the preprocessed measurement sample, and the remaining components (Including a part of the function of the control unit 120) is a pretreatment means for performing a pretreatment including a solid phase extraction process on the measurement sample.
<自動分析装置100による濃度測定>
 次に、自動分析装置100による血清試料中のテオフィリン濃度測定手順について、図1を参照しつつ図2を用いて説明する。図2は、第1実施形態に係る自動分析装置100による固相抽出前処理の工程を示すチャートである。
 図2の処理に先立って、血清試料(測定試料)を試料容器101に分注して格納し、試料設置部102にセットする。このとき、例えば、検体ID、試料の液性、測定対象薬物などの試料に関する情報(試料情報)を記録したバーコード121があらかじめ作成されており、図3のように試料容器101の側面にバーコード121が貼付されている。
<Concentration measurement by automatic analyzer 100>
Next, a procedure for measuring theophylline concentration in a serum sample by the automatic analyzer 100 will be described with reference to FIG. 1 and FIG. FIG. 2 is a chart showing steps of solid phase extraction pretreatment by the automatic analyzer 100 according to the first embodiment.
Prior to the processing of FIG. 2, a serum sample (measurement sample) is dispensed and stored in the sample container 101 and set in the sample setting unit 102. At this time, for example, a bar code 121 in which information (sample information) related to the sample such as the specimen ID, the liquid property of the sample, and the drug to be measured is recorded is prepared in advance. A code 121 is attached.
 図2の説明に戻り、自動分析装置100は、以下のような工程で血清試料中のテオフィリン濃度を測定する。
(工程1:試料情報読み込み)
 自動分析装置100は、試料容器101が設置された試料設置部102を回転させ、試料容器101を試料情報読み取り部103の前を通過させる。試料情報読み取り部103は、試料容器101のバーコード121から試料情報を読み取り、読み取った情報を制御部120に送る。
Returning to the description of FIG. 2, the automatic analyzer 100 measures the theophylline concentration in the serum sample in the following steps.
(Step 1: Read sample information)
The automatic analyzer 100 rotates the sample setting unit 102 in which the sample container 101 is set, and passes the sample container 101 in front of the sample information reading unit 103. The sample information reading unit 103 reads sample information from the barcode 121 of the sample container 101 and sends the read information to the control unit 120.
(工程2:前処理条件呼び出し)
 制御部120には、試料種類および薬物ごとに、試料量、抽出材の種類および量、固相抽出条件(洗浄液、溶出液の種類および量、加圧条件など)などの前処理条件と、質量分析(MS)測定条件とがあらかじめデータベースDBとして記憶されている。ある薬物に対して、濃度分析を行う際に用いられる試料種類が複数ある場合は、その薬物に対してそれぞれの試料種類別にデータベースが作成されている。制御部120は、試料情報読み取り部103から送られてきた試料情報から、テオフィリン測定に使用する前処理条件と質量分析(MS)測定条件を装置制御パラメータとして呼び出し、装置各部に送信する。
(Process 2: Call preconditions)
The control unit 120 includes, for each sample type and drug, pretreatment conditions such as sample amount, type and amount of extraction material, solid-phase extraction conditions (such as type and amount of washing liquid and eluate, pressurization condition), and mass. Analysis (MS) measurement conditions are stored in advance as a database DB. When there are a plurality of sample types used for concentration analysis for a certain drug, a database is created for each sample type for that drug. The control unit 120 calls the preprocessing conditions and mass spectrometry (MS) measurement conditions used for theophylline measurement from the sample information sent from the sample information reading unit 103 as device control parameters, and transmits them to each unit of the device.
 テオフィリンの場合、治療域は10~20μg/mLであり、自動分析装置100は治療域を含む1~50μg/mL程度の濃度範囲で定量する必要がある。この濃度範囲は、テオフィリンに対する質量分析(MS)の検出感度から考えるとかなり高い濃度範囲であるため、使用する検体量は少量でよく、例えば20μL程度で十分である。同様に、想定濃度範囲のテオフィリン測定に最適化された固相抽出材の量や洗浄液、溶出液などに関するパラメータが呼び出されて装置各部に送信される。 In the case of theophylline, the therapeutic range is 10 to 20 μg / mL, and the automatic analyzer 100 needs to quantify in a concentration range of about 1 to 50 μg / mL including the therapeutic range. This concentration range is a considerably high concentration range in view of detection sensitivity of mass spectrometry (MS) for theophylline, and therefore, a small amount of sample may be used, for example, about 20 μL is sufficient. Similarly, parameters relating to the amount of the solid-phase extraction material optimized for theophylline measurement in the assumed concentration range, the washing solution, and the eluate are called and transmitted to each part of the apparatus.
(工程3:抽出材液スラリ注入)
 抽出材液分注機構106は、制御部120から送信された装置制御パラメータに基づいて、設定された一定量の抽出材液スラリを抽出材液容器105から分注し、固相抽出カートリッジ104に注入する。抽出材液は、固相抽出材を含んだ水あるいはメタノールなどの有機溶媒である。固相抽出材としては、例えば逆相固相抽出材である日立ハイテクノロジーズ社製「NOBIAS RP-SG1」が使用できる。この場合、溶媒としては50%メタノール水溶液が適する。また抽出材液スラリの比率は、固相抽出材20mgに対して50%メタノール水溶液1mLが適する。
(Process 3: Extraction material liquid slurry injection)
The extraction material liquid dispensing mechanism 106 dispenses a set amount of the extracted material liquid slurry from the extraction material liquid container 105 based on the device control parameter transmitted from the control unit 120, and supplies it to the solid phase extraction cartridge 104. inject. The extraction material liquid is an organic solvent such as water or methanol containing a solid phase extraction material. As the solid phase extraction material, for example, “NOBIAS RP-SG1” manufactured by Hitachi High-Technologies Corporation, which is a reverse phase solid phase extraction material, can be used. In this case, a 50% aqueous methanol solution is suitable as the solvent. The ratio of the extraction material liquid slurry is suitably 1 mL of 50% methanol aqueous solution with respect to 20 mg of the solid phase extraction material.
 抽出材液スラリは、攪拌機構107によって分注前に十分攪拌され、固相抽出材の均一なスラリを形成する。攪拌機構107としては、マグネティックスターラが簡便である。マグネティックスターラは、棒磁石をテフロン(登録商標)樹脂などで被った攪拌子を攪拌対象物質(この場合は抽出材液スラリ)中に投入しておき、抽出材液容器105の下部に設置された攪拌機構107の内部にある磁石をモータで回転させるものである。マグネティックスターラで攪拌することで、均一なスラリを形成することができる。抽出材液スラリが注入された固相抽出カートリッジ104は、加圧機構113によって上方から加圧されて溶媒が下方に通過する。 The extraction material liquid slurry is sufficiently stirred before dispensing by the stirring mechanism 107 to form a uniform slurry of the solid phase extraction material. As the stirring mechanism 107, a magnetic stirrer is simple. In the magnetic stirrer, a stirrer covered with a Teflon (registered trademark) resin or the like with a bar magnet is put into a substance to be stirred (in this case, an extractant liquid slurry), and installed in the lower part of the extractant liquid container 105. The magnet inside the stirring mechanism 107 is rotated by a motor. By stirring with a magnetic stirrer, a uniform slurry can be formed. The solid phase extraction cartridge 104 into which the extraction material liquid slurry has been injected is pressurized from above by the pressurizing mechanism 113, and the solvent passes downward.
 図4は、固相抽出カートリッジ104の構造を示す断面図である。固相抽出カートリッジ104の内部下方にはフィルタ122が設置されている。本実施形態においては、フィルタ122の孔径は10μmとした。このような構造によれば、加圧機構113によって加圧された溶媒は固相抽出カートリッジ104を通過する一方、固相抽出材はフィルタ122の上部に残留する。 FIG. 4 is a cross-sectional view showing the structure of the solid phase extraction cartridge 104. A filter 122 is installed below the inside of the solid-phase extraction cartridge 104. In the present embodiment, the hole diameter of the filter 122 is 10 μm. According to such a structure, the solvent pressurized by the pressurizing mechanism 113 passes through the solid phase extraction cartridge 104, while the solid phase extraction material remains on the filter 122.
(工程4:平衡化)
 固相抽出材の平衡化のため、溶媒の通過後の固相抽出カートリッジ104に対して、試薬配置部110に配置された純水を試薬分注機構112によって分注する。注入された純水は加圧機構113によって加圧されて固相抽出カートリッジ104の下方に通過する。ここまでの工程で試料処理の準備が終了する。
(Step 4: Equilibration)
In order to equilibrate the solid phase extraction material, pure water arranged in the reagent arrangement unit 110 is dispensed by the reagent dispensing mechanism 112 to the solid phase extraction cartridge 104 after passing through the solvent. The injected pure water is pressurized by the pressurizing mechanism 113 and passes below the solid phase extraction cartridge 104. The preparation for sample processing is completed by the steps so far.
(工程5:試料注入)
 試薬分注機構112は、試薬配置部110からテオフィリンの内標準物質(テオフィリン-d6)溶液を分注し、固相抽出材が注入され試料処理準備が終了した固相抽出カートリッジ104に注入する。続いて、試料分注機構111は、試料容器101から血清試料(測定試料)を分注し、内標準物質が注入された固相抽出カートリッジ104に注入する。固相抽出カートリッジ104に注入された血清試料および内標準物質液は、加圧機構113によって上方より加圧されて固相抽出材を通過し、下方に排出される。この工程によって、血清試料中に含まれるテオフィリン(薬物)と内標準物質は、疎水性相互作用により固相抽出材表面に選択的に吸着する。
(Step 5: Sample injection)
The reagent dispensing mechanism 112 dispenses a theophylline internal standard substance (theophylline-d6) solution from the reagent placement unit 110 and injects it into the solid phase extraction cartridge 104 in which the solid phase extraction material has been injected and the sample processing preparation has been completed. Subsequently, the sample dispensing mechanism 111 dispenses a serum sample (measurement sample) from the sample container 101 and injects it into the solid phase extraction cartridge 104 into which the internal standard substance has been injected. The serum sample and the internal standard substance liquid injected into the solid phase extraction cartridge 104 are pressurized from above by the pressurizing mechanism 113, pass through the solid phase extraction material, and discharged downward. By this step, theophylline (drug) and the internal standard substance contained in the serum sample are selectively adsorbed on the surface of the solid-phase extraction material by hydrophobic interaction.
(工程6:洗浄)
 試薬分注機構112は、試薬容器109に格納された洗浄液としての純水200μLを分注する。そして、加圧機構113によって加圧処理を行うことで固相抽出カートリッジ104を洗浄する。この工程によって、固相抽出材表面に非特異的に残存した血清試料中の成分を排出する。
(Step 6: Washing)
The reagent dispensing mechanism 112 dispenses 200 μL of pure water as a cleaning liquid stored in the reagent container 109. Then, the solid-phase extraction cartridge 104 is washed by performing a pressure treatment by the pressure mechanism 113. By this step, components in the serum sample remaining nonspecifically on the surface of the solid-phase extraction material are discharged.
(工程7:溶出)
 洗浄後、試薬分注機構112は、溶出液として50%メタノール水溶液100μLを固相抽出カートリッジ104に分注する。そして、加圧機構113によって加圧処理を行うことで固相抽出カートリッジ104からテオフィリン(薬物)およびテオフィリン-d6(内標準物質)を溶出させた抽出試料液を抽出容器114で回収する。
(Step 7: Elution)
After washing, the reagent dispensing mechanism 112 dispenses 100 μL of 50% methanol aqueous solution as an eluent into the solid phase extraction cartridge 104. The extraction sample solution in which theophylline (drug) and theophylline-d6 (internal standard substance) are eluted from the solid-phase extraction cartridge 104 is collected in the extraction container 114 by performing a pressurizing process with the pressurizing mechanism 113.
 自動分析装置100は、抽出試料液を回収した抽出容器114を、抽出容器設置部115の回転によって試料導入部117の位置に移動する。抽出試料液は、試料導入部117によってイオン源118に導入される。イオン源118でテオフィリン(薬物)およびテオフィリン-d6(内標準物質)がイオン化され、質量分析部119で両成分が検出される。検出された両成分の信号強度は、制御部120に転送される。制御部120は、転送された両成分の信号強度比と、あらかじめ求めておいたキャリブレータの信号強度比から、血清試料中のテオフィリン濃度を計算する。
 以上のような工程で自動分析装置100は、血清試料中のテオフィリン濃度を測定する。
The automatic analyzer 100 moves the extraction container 114 from which the extraction sample solution has been collected to the position of the sample introduction unit 117 by the rotation of the extraction container installation unit 115. The extracted sample solution is introduced into the ion source 118 by the sample introduction unit 117. Theophylline (drug) and theophylline-d6 (internal standard substance) are ionized by the ion source 118, and both components are detected by the mass spectrometer 119. The detected signal strengths of both components are transferred to the control unit 120. The control unit 120 calculates the theophylline concentration in the serum sample from the transferred signal intensity ratio of both components and the signal intensity ratio of the calibrator obtained in advance.
In the process as described above, the automatic analyzer 100 measures the theophylline concentration in the serum sample.
<まとめ>
 以上説明したように、自動分析装置100は、様々な種類の薬物の定量測定を行うにあたって、それぞれの薬物や測定対象試料の種類に対応する前処理条件をデータベース化しておき、当該データベースの値に従って固相抽出処理を含む前処理を行う。これにより、常に最適な固相抽出材、試料、各種試薬の使用量を選択することができ、無駄な試薬消費を抑え、分析処理にかかるランニングコストを低減することができる。
<Summary>
As described above, when the automatic analyzer 100 performs quantitative measurement of various types of drugs, the pretreatment conditions corresponding to the types of each drug and the sample to be measured are stored in a database, and according to the values of the database. Pretreatment including solid phase extraction is performed. As a result, it is possible to always select the optimal amount of solid phase extraction material, sample, and various reagents, to suppress unnecessary reagent consumption and to reduce the running cost for analysis processing.
 また、従来技術の分析装置によれば、固相抽出材の種類別および使用量別に、異なる複数の固相抽出カートリッジを備えなければならなかった。一方、自動分析装置100では、固相抽出材が封入された固相抽出カートリッジをあらかじめ備える必要がないので、装置構成を簡素化することができ、装置自体の製造コストを低減することができる。 In addition, according to the analyzer of the prior art, it has been necessary to provide a plurality of different solid phase extraction cartridges for each type and amount of solid phase extraction material. On the other hand, in the automatic analyzer 100, since it is not necessary to provide a solid phase extraction cartridge in which a solid phase extraction material is sealed in advance, the apparatus configuration can be simplified and the manufacturing cost of the apparatus itself can be reduced.
≪第2実施形態≫
<自動分析装置500の構成>
 図5は、第2実施形態に係る自動分析装置500の構成図である。
 第2実施形態に係る自動分析装置500は、第1実施形態に係る自動分析装置100と比較して、固相抽出カートリッジ104に対して容器内を攪拌する攪拌機構123を設けた点が異なっている。
 攪拌機構123は、例えば超音波攪拌機を使用することができる。攪拌機構123を設けることによって、固相抽出カートリッジ104内の試料と固相抽出材などの試薬との接触率を向上させることができ、例えば、測定試料内の測定対象物質(薬物)の濃度が低い場合でも精度よく測定を行うことができる。
<< Second Embodiment >>
<Configuration of automatic analyzer 500>
FIG. 5 is a configuration diagram of an automatic analyzer 500 according to the second embodiment.
The automatic analyzer 500 according to the second embodiment is different from the automatic analyzer 100 according to the first embodiment in that a stirring mechanism 123 that stirs the inside of the container with respect to the solid phase extraction cartridge 104 is provided. Yes.
As the stirring mechanism 123, for example, an ultrasonic stirrer can be used. By providing the stirring mechanism 123, the contact rate between the sample in the solid-phase extraction cartridge 104 and a reagent such as a solid-phase extraction material can be improved. For example, the concentration of the measurement target substance (drug) in the measurement sample can be increased. Even if it is low, it is possible to measure accurately.
 自動分析装置500は、測定試料に含まれる薬物の濃度を自動で連続的に測定することができる分析装置であり、第2実施形態では全血試料中に含まれる免疫抑制剤タクロリムス(薬物)の濃度を分析するものとして説明する。
 全血試料中のタクロリムスは血球成分中に存在するため、そのままの状態では固相抽出処理を行うことができない。第2実施形態では、全血試料に対して3倍量の0.5M硫酸亜鉛水溶液および4倍量の10ng/mL濃度のアスコマシンを含むメタノール溶液(全血試料50μLに対して0.5M硫酸亜鉛水溶液150μLならびにメタノール溶液200μL)を添加することによって、血球破壊と沈殿の形成を行い、遠心分離後の上清を全血処理液試料(測定試料)として用いる。ここで、アスコマイシンは、タクロリムスの内標準物質として質量分析(MS)測定時に使用される。
The automatic analyzer 500 is an analyzer that can automatically and continuously measure the concentration of a drug contained in a measurement sample. In the second embodiment, the immunosuppressant tacrolimus (drug) contained in a whole blood sample is used. It is assumed that the concentration is analyzed.
Since tacrolimus in the whole blood sample is present in blood cell components, solid phase extraction cannot be performed as it is. In the second embodiment, a methanol solution containing 3 times the amount of 0.5 M zinc sulfate aqueous solution and 4 times the amount of 10 ng / mL concentration of ascomachine (0.5 M sulfuric acid for 50 μL of the whole blood sample). By adding 150 μL of aqueous zinc solution and 200 μL of methanol solution, blood cells are destroyed and precipitates are formed, and the supernatant after centrifugation is used as a whole blood treatment liquid sample (measurement sample). Here, ascomycin is used at the time of mass spectrometry (MS) measurement as an internal standard substance of tacrolimus.
 また、第2実施形態では、前処理においてバッチ式で固相抽出処理を行う。ここでいうバッチ式とは、固相抽出材をカートリッジの一部分に固定することなく、測定試料液内を自由に移動させることで測定試料中の薬物と固相抽出させる方式のことである。 Further, in the second embodiment, the solid phase extraction process is performed in a batch manner in the pretreatment. Here, the batch type refers to a system in which solid phase extraction is performed with the drug in the measurement sample by freely moving the measurement sample solution without fixing the solid phase extraction material to a part of the cartridge.
<自動分析装置500による濃度測定>
 次に、自動分析装置500による全血試料中のタクロリムス濃度測定手順について、図5を参照しつつ図6を用いて説明する。図6は、第2実施形態に係る自動分析装置500による固相抽出前処理の工程を示すチャートである。
 図6の処理に先立って、全血処理液試料(測定試料)を試料容器101に分注して格納し、試料設置部102にセットするとともに、試料情報を記録したバーコード121(図3参照)を試料容器101の側面に貼付しておく。
<Concentration measurement by automatic analyzer 500>
Next, a procedure for measuring tacrolimus concentration in a whole blood sample by the automatic analyzer 500 will be described with reference to FIG. 5 and FIG. FIG. 6 is a chart showing steps of solid phase extraction pretreatment by the automatic analyzer 500 according to the second embodiment.
Prior to the processing of FIG. 6, a whole blood processing solution sample (measurement sample) is dispensed and stored in the sample container 101, set in the sample setting unit 102, and a barcode 121 in which sample information is recorded (see FIG. 3) ) Is attached to the side surface of the sample container 101.
(工程1:試料情報読み込み)
 第1実施形態の(工程1:試料情報読み込み)(図2参照)と同様に行う。
(Step 1: Read sample information)
This is performed in the same manner as (Step 1: Reading sample information) (see FIG. 2) of the first embodiment.
(工程2:前処理条件呼び出し)
 制御部120は、試料情報読み取り部103から送られてきた試料情報から、タクロリムス測定に使用する前処理条件と質量分析(MS)測定条件を装置制御パラメータとして呼び出し、装置各部に送信する。
(Process 2: Call preconditions)
The control unit 120 calls the preprocessing conditions and mass spectrometry (MS) measurement conditions used for tacrolimus measurement as device control parameters from the sample information sent from the sample information reading unit 103, and transmits them to each unit of the device.
 タクロリムスの場合、治療域は2~20ng/mLであり、自動分析装置500としては治療域を含む0.5~30ng/mL程度の濃度範囲で定量することが要求される。このように全血中のタクロリムスは、例えば第1実施形態で挙げたテオフィリンなどと比較して低濃度であり、自動分析装置500で精度よく測定するには、検体量は200μL必要である。同様に、想定濃度範囲のタクロリムス測定に最適化された固相抽出材の量や洗浄液、溶出液などに関するパラメータが呼び出されて装置各部に送信される。 In the case of tacrolimus, the therapeutic range is 2 to 20 ng / mL, and the automatic analyzer 500 is required to perform quantification in a concentration range of about 0.5 to 30 ng / mL including the therapeutic range. Thus, tacrolimus in whole blood has a lower concentration than, for example, theophylline mentioned in the first embodiment, and a sample amount of 200 μL is required for accurate measurement by the automatic analyzer 500. Similarly, parameters relating to the amount of the solid-phase extraction material optimized for the measurement of tacrolimus in the assumed concentration range, the washing liquid, the eluate, etc. are called and transmitted to each part of the apparatus.
(工程3:抽出材液スラリ注入)
 第1実施形態の(工程3:抽出材液スラリ注入)(図2参照)と同様に、抽出材液分注機構106は、制御部120から送信された装置制御パラメータに基づいて、設定された一定量の抽出材液スラリを抽出材液容器105から分注し、固相抽出カートリッジ104に注入する。そして、抽出材液スラリが注入された固相抽出カートリッジ104は、加圧機構113によって上方から加圧されて溶媒が下方に通過する。
(Process 3: Extraction material liquid slurry injection)
Similar to the (step 3: extraction material liquid slurry injection) of the first embodiment (see FIG. 2), the extraction material liquid dispensing mechanism 106 is set based on the apparatus control parameter transmitted from the control unit 120. A certain amount of extraction material liquid slurry is dispensed from the extraction material liquid container 105 and injected into the solid phase extraction cartridge 104. The solid-phase extraction cartridge 104 into which the extraction material liquid slurry has been injected is pressurized from above by the pressurizing mechanism 113, and the solvent passes downward.
(工程5A:試料注入)
 試料分注機構111は、試料容器101から全血処理液試料(測定試料)を分注し、固相抽出材が注入された固相抽出カートリッジ104に注入する。
(Step 5A: Sample injection)
The sample dispensing mechanism 111 dispenses the whole blood processing liquid sample (measurement sample) from the sample container 101 and injects it into the solid phase extraction cartridge 104 into which the solid phase extraction material has been injected.
(工程5B:攪拌)
 自動分析装置100は、処理部108を回転させることにより、固相抽出材および全血処理液試料が(測定試料)分注された固相抽出カートリッジ104を攪拌機構123の位置に移動させ、固相抽出材と全血処理液試料の攪拌を行う。この攪拌によって、固相抽出材と試料液中のタクロリムスおよび内標準アスコマイシンが十分な回数接触することができ、固相抽出材に吸着する。
(Step 5B: stirring)
The automatic analyzer 100 rotates the processing unit 108 to move the solid-phase extraction cartridge 104 into which the solid-phase extraction material and the whole blood processing liquid sample (measurement sample) are dispensed to the position of the stirring mechanism 123, thereby Stir the phase extraction material and the whole blood treatment liquid sample. By this stirring, the solid phase extraction material, tacrolimus in the sample solution and the internal standard ascomycin can be brought into contact with each other a sufficient number of times, and are adsorbed on the solid phase extraction material.
(工程5C:吐出)
 自動分析装置100は、処理部108を回転させることにより、攪拌が十分に行われた固相抽出カートリッジ104を加圧機構113の位置に移動させる。加圧機構113の加圧処理によって固相抽出カートリッジ104内の全血処理液試料は下方に通過する。一方、タクロリムスとアスコマイシンは固相抽出材に吸着されたままであり、固相抽出材と共にカートリッジ内のフィルタ122の上部に残留する。
(Process 5C: Discharge)
The automatic analyzer 100 rotates the processing unit 108 to move the solid-phase extraction cartridge 104 that has been sufficiently stirred to the position of the pressurizing mechanism 113. The whole blood processing liquid sample in the solid-phase extraction cartridge 104 passes downward by the pressurizing process of the pressurizing mechanism 113. On the other hand, tacrolimus and ascomycin remain adsorbed on the solid phase extraction material, and remain on the upper part of the filter 122 in the cartridge together with the solid phase extraction material.
(工程6:洗浄)
 第1実施形態の(工程6:洗浄)(図2参照)と同様に、試薬分注機構112は、試薬容器109に格納された洗浄液としての純水200μLを分注する。そして、加圧機構113によって加圧処理を行うことで固相抽出カートリッジ104を洗浄する。この工程によって、固相抽出材表面に非特異的に残存した全血処理液試料中の成分を排出する。
(Step 6: Washing)
Similar to (Step 6: Washing) of the first embodiment (see FIG. 2), the reagent dispensing mechanism 112 dispenses 200 μL of pure water as a washing liquid stored in the reagent container 109. Then, the solid-phase extraction cartridge 104 is washed by performing a pressure treatment by the pressure mechanism 113. By this step, the components in the whole blood processing liquid sample remaining non-specifically on the surface of the solid-phase extraction material are discharged.
(工程7:溶出)
 洗浄後、試薬分注機構112は、溶出液としてメタノール50μLを固相抽出カートリッジ104に分注する。そして、加圧機構113によって加圧処理を行うことで固相抽出カートリッジ104からタクロリムス(薬物)およびアスコマイシン(内標準物質)を溶出させた抽出試料液を抽出容器114に回収する。
(Step 7: Elution)
After washing, the reagent dispensing mechanism 112 dispenses 50 μL of methanol as an eluent to the solid phase extraction cartridge 104. Then, the extraction sample solution in which tacrolimus (drug) and ascomycin (internal standard substance) are eluted from the solid-phase extraction cartridge 104 is recovered in the extraction container 114 by performing a pressurizing process by the pressurizing mechanism 113.
 自動分析装置500は、抽出試料液を回収した抽出容器114を、抽出容器設置部115の回転によって試料導入部117の位置に移動する。抽出試料液は、試料導入部117によってイオン源118に導入される。イオン源118でタクロリムス(薬物)およびアスコマイシン(内標準物質)がイオン化され、質量分析部119で両成分が検出される。検出された両成分の信号強度は制御部120に転送される。制御部120は、転送された両成分の信号強度比と、あらかじめ求めておいたキャリブレータの信号強度比から、全血試料中のタクロリムス濃度を計算する。
 以上のような工程で自動分析装置500は、全血試料中のタクロリムス濃度を測定する。
The automatic analyzer 500 moves the extraction container 114 from which the extraction sample solution has been collected to the position of the sample introduction unit 117 by the rotation of the extraction container installation unit 115. The extracted sample solution is introduced into the ion source 118 by the sample introduction unit 117. Tacrolimus (drug) and ascomycin (internal standard substance) are ionized by the ion source 118, and both components are detected by the mass spectrometer 119. The detected signal strengths of both components are transferred to the control unit 120. The control unit 120 calculates the tacrolimus concentration in the whole blood sample from the transferred signal intensity ratio of both components and the signal intensity ratio of the calibrator obtained in advance.
In the process as described above, the automatic analyzer 500 measures the tacrolimus concentration in the whole blood sample.
 以上説明したように、自動分析装置500によれば、第1実施形態に係る自動分析装置100と同様の効果に加えて、試料内の測定対象物質濃度が低い場合でも精度よく測定を行うことができる。 As described above, according to the automatic analyzer 500, in addition to the same effects as those of the automatic analyzer 100 according to the first embodiment, it is possible to accurately measure even when the concentration of the measurement target substance in the sample is low. it can.
≪変形例≫
 なお、本実施形態に係る自動分析装置は、上記実施形態の構成に限定されるものではなく、発明の趣旨を逸脱しない範囲内で種々の変更が可能である。
 第1および第2実施形態では、単一の固相抽出材を用いた測定について説明したが、1つの固相抽出カートリッジに対して複数の固相抽出材を供給することも可能である。具体的には、抽出材液分注機構106の動作線上にそれぞれ異なる種類の固相抽出材を入れた抽出材液容器105を複数配置して、(工程3:抽出材液スラリ注入)を複数回繰り返すことで実現することができる。このような方法は、例えば、スルホン酸基を有する陽イオン交換系固相抽出材と逆相固相抽出材を混合することで固相抽出効率が改善する薬物を測定する場合などに有効である。このような方法を採る場合、洗浄液や溶出液のpHの最適化、溶出液の種類や量を変更などの必要があるが、自動分析装置100,500を用いればこれらの変更は容易である。
≪Modification≫
The automatic analyzer according to the present embodiment is not limited to the configuration of the above-described embodiment, and various modifications can be made without departing from the spirit of the invention.
In the first and second embodiments, the measurement using a single solid phase extraction material has been described, but it is also possible to supply a plurality of solid phase extraction materials to one solid phase extraction cartridge. Specifically, a plurality of extraction material liquid containers 105 each containing different types of solid phase extraction materials are arranged on the operation line of the extraction material liquid dispensing mechanism 106, and a plurality of (Step 3: extraction material liquid slurry injection) are arranged. It can be realized by repeating it. Such a method is effective, for example, when measuring a drug whose solid-phase extraction efficiency is improved by mixing a cation exchange solid-phase extraction material having a sulfonic acid group and a reverse-phase solid-phase extraction material. . In the case of adopting such a method, it is necessary to optimize the pH of the washing solution or the eluate and to change the type and amount of the eluate, but these changes are easy if the automatic analyzers 100 and 500 are used.
 本実施形態に係る自動分析装置100,500の質量分析部119は、抽出試料液中の薬物の濃度を測定する定量分析を行うものとして説明したが、これに限られるものではなく、抽出試料液中の薬物の物質を同定する定性分析を行うものであってもよく、定性分析と定量分析を同時に行うものであってもよい。 Although the mass spectrometer 119 of the automatic analyzers 100 and 500 according to the present embodiment has been described as performing quantitative analysis for measuring the concentration of a drug in the extracted sample solution, the present invention is not limited to this, and the extracted sample solution is not limited thereto. A qualitative analysis for identifying the substance of the drug in the drug may be performed, or a qualitative analysis and a quantitative analysis may be performed simultaneously.
 本発明に係る分析装置は、測定試料に含まれる薬物の濃度を測定する分析装置に有効であり、特に、LC-MS(またはLC-MS/MS)分析装置のような質量分析計を用いて生体試料に含まれる薬物の濃度を測定する分析装置に適している。 The analyzer according to the present invention is effective as an analyzer for measuring the concentration of a drug contained in a measurement sample, and particularly using a mass spectrometer such as an LC-MS (or LC-MS / MS) analyzer. It is suitable for an analyzer that measures the concentration of a drug contained in a biological sample.
100  自動分析装置(分析装置)
101  試料容器
102  試料設置部(前処理手段)
103  試料情報読み取り部(前処理手段)
104  固相抽出カートリッジ(固相抽出用容器)
105  抽出材液容器(スラリ生成手段)
106  抽出材液分注機構(固相抽出材分注手段)
107  攪拌機構(スラリ生成手段)
108  処理部(前処理手段)
109  試薬容器
110  試薬配置部(前処理手段)
111  試料分注機構(前処理手段)
112  試薬分注機構(前処理手段)
113  加圧機構(前処理手段)
114  抽出容器
115  抽出容器設置部(前処理手段)
116  消耗品設置部
117  試料導入部(前処理手段)
118  イオン源(測定手段)
119  質量分析部(測定手段)
120  制御部
123  攪拌機構(攪拌手段)
500  自動分析装置(分析装置)
100 Automatic analyzer (analyzer)
101 Sample container 102 Sample installation part (pretreatment means)
103 Sample information reading unit (pretreatment means)
104 Solid phase extraction cartridge (solid phase extraction container)
105 Extraction material liquid container (slurry generating means)
106 Extraction material liquid dispensing mechanism (Solid phase extraction material dispensing means)
107 Stirring mechanism (slurry generating means)
108 processing unit (pre-processing means)
109 Reagent container 110 Reagent placement part (pretreatment means)
111 Sample dispensing mechanism (pretreatment means)
112 Reagent dispensing mechanism (pretreatment means)
113 Pressurizing mechanism (pretreatment means)
114 Extraction container 115 Extraction container installation part (pretreatment means)
116 Consumables installation unit 117 Sample introduction unit (pretreatment means)
118 Ion source (measuring means)
119 Mass Spectrometer (Measuring means)
120 control part 123 stirring mechanism (stirring means)
500 Automatic analyzer (analyzer)

Claims (11)

  1.  測定試料に含まれる薬物を測定する分析装置であって、
     固相抽出用容器内に固相抽出材を注入する固相抽出材分注手段と、
     前記固相抽出材が注入された前記固相抽出用容器内に前記測定試料を注入して固体抽出処理により抽出試料液を生成する前処理手段と、
     前記抽出試料液中の前記薬物を測定する測定手段と、を備える
    ことを特徴とする分析装置。
    An analyzer for measuring a drug contained in a measurement sample,
    A solid phase extraction material dispensing means for injecting the solid phase extraction material into the solid phase extraction container;
    Pretreatment means for injecting the measurement sample into the solid phase extraction container into which the solid phase extraction material has been injected and generating an extraction sample liquid by solid extraction processing;
    And an analyzer that measures the drug in the extracted sample solution.
  2.  前記固相抽出材および溶媒を攪拌して固相抽出材スラリを生成するスラリ生成手段を更に備え、
     前記固相抽出材分注手段は、
     前記スラリ生成手段で生成された前記固相抽出材スラリを前記固相抽出用容器内に注入する
    ことを特徴とする請求項1に記載の分析装置。
    A slurry generation means for stirring the solid phase extraction material and the solvent to generate a solid phase extraction material slurry,
    The solid phase extraction material dispensing means includes:
    The analyzer according to claim 1, wherein the solid phase extraction material slurry generated by the slurry generating means is injected into the solid phase extraction container.
  3.  前記前処理手段は、
     前記固相抽出用容器内に注入された前記固相抽出材および前記測定試料を、前記固相抽出用容器内で攪拌する攪拌手段を有する
    ことを特徴とする請求項1に記載の分析装置。
    The preprocessing means includes
    2. The analyzer according to claim 1, further comprising a stirring unit that stirs the solid-phase extraction material and the measurement sample injected into the solid-phase extraction container in the solid-phase extraction container.
  4.  前記測定手段は、前記抽出試料液中の前記薬物の物質を同定する定性分析を行う
    ことを特徴とする請求項1に記載の分析装置。
    The analyzer according to claim 1, wherein the measuring unit performs a qualitative analysis for identifying a substance of the drug in the extracted sample solution.
  5.  前記測定手段は、前記抽出試料液中の前記薬物の濃度を測定する定量分析を行う
    ことを特徴とする請求項1に記載の分析装置。
    The analyzer according to claim 1, wherein the measuring unit performs a quantitative analysis for measuring the concentration of the drug in the extracted sample solution.
  6.  前記固相抽出材分注手段は、
     前記測定試料に含まれる前記薬物の想定される濃度に基づいて、前記固相抽出用容器内に注入する前記固相抽出材の量を変更する
    ことを特徴とする請求項5に記載の分析装置。
    The solid phase extraction material dispensing means includes:
    6. The analyzer according to claim 5, wherein an amount of the solid phase extraction material injected into the solid phase extraction container is changed based on an assumed concentration of the drug contained in the measurement sample. .
  7.  前記前処理手段は、
     前記測定試料に含まれる前記薬物の想定される濃度に基づいて、前記固相抽出用容器内に注入する前記測定試料の量を変更する
    ことを特徴とする請求項5に記載の分析装置。
    The preprocessing means includes
    The analyzer according to claim 5, wherein the amount of the measurement sample injected into the solid phase extraction container is changed based on an assumed concentration of the drug contained in the measurement sample.
  8.  前記固相抽出材分注手段は、
     1つの前記固相抽出用容器に対して、複数種類の固相抽出材を注入する
    ことを特徴とする請求項1に記載の分析装置。
    The solid phase extraction material dispensing means includes:
    The analyzer according to claim 1, wherein a plurality of types of solid phase extraction materials are injected into one said solid phase extraction container.
  9.  前記測定手段は、質量分析計である
    ことを特徴とする請求項1に記載の分析装置。
    The analyzer according to claim 1, wherein the measuring unit is a mass spectrometer.
  10.  前記測定試料は、血液、血清、尿、唾液を含む生体液である
    ことを特徴とする請求項1に記載の分析装置。
    The analyzer according to claim 1, wherein the measurement sample is a biological fluid including blood, serum, urine, and saliva.
  11.  測定試料に含まれる薬物を測定する分析装置による分析方法あって、
     固相抽出用容器内に固相抽出材を注入する注入処理と、
     前記注入処理により前記固相抽出材が注入された前記固相抽出用容器内に前記測定試料
    を注入して固体抽出処理により抽出試料液を生成する前処理と、
     前記前処理により前記抽出試料液中の前記薬物を測定する測定処理と、を実行する
    ことを特徴とする分析方法。
    There is an analysis method by an analyzer for measuring a drug contained in a measurement sample,
    An injection process for injecting a solid-phase extraction material into a solid-phase extraction container;
    A pre-process for injecting the measurement sample into the solid-phase extraction container into which the solid-phase extraction material has been injected by the injection process and generating an extraction sample liquid by a solid extraction process;
    And performing a measurement process for measuring the drug in the extracted sample solution by the pretreatment.
PCT/JP2012/077717 2011-10-28 2012-10-26 Analysis device and analysis method WO2013062084A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-237117 2011-10-28
JP2011237117A JP2013096733A (en) 2011-10-28 2011-10-28 Analytical device and analytical method

Publications (1)

Publication Number Publication Date
WO2013062084A1 true WO2013062084A1 (en) 2013-05-02

Family

ID=48167908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/077717 WO2013062084A1 (en) 2011-10-28 2012-10-26 Analysis device and analysis method

Country Status (2)

Country Link
JP (1) JP2013096733A (en)
WO (1) WO2013062084A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104266885A (en) * 2014-07-25 2015-01-07 安徽省一一通信息科技有限公司 Sample automatic-treatment system
CN105452871A (en) * 2013-08-23 2016-03-30 株式会社日立高新技术 Analysis device and analysis method
CN105784455A (en) * 2016-05-16 2016-07-20 张起香 Extraction structure and liquid pretreatment device
CN113960224A (en) * 2021-09-26 2022-01-21 裕菁科技(上海)有限公司 Additive applied to liquid-liquid extraction pretreatment of biological sample and extraction method

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115166107A (en) * 2016-02-03 2022-10-11 科思德株式会社 Element for extracting organic components
JP6784196B2 (en) * 2017-03-03 2020-11-11 株式会社島津製作所 Analysis system equipped with a pretreatment device and its pretreatment device
JP7470362B2 (en) * 2020-01-29 2024-04-18 株式会社テクノメデイカ Urine collection cup management device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005091007A (en) * 2003-09-12 2005-04-07 Hitachi Sci Syst Ltd Plate column device for pin spot
WO2005098416A1 (en) * 2004-03-31 2005-10-20 Saika Technological Institute Foundation Stationary phase extraction cartridge
JP2008020275A (en) * 2006-07-12 2008-01-31 Hitachi Koki Co Ltd Automatic solid-phase extractor
JP2011089924A (en) * 2009-10-23 2011-05-06 Hitachi High-Technologies Corp Drug analysis device
JP2011095069A (en) * 2009-10-29 2011-05-12 Hitachi High-Technologies Corp Clinical examination system, clinical examination method, and equipment for pretreatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005091007A (en) * 2003-09-12 2005-04-07 Hitachi Sci Syst Ltd Plate column device for pin spot
WO2005098416A1 (en) * 2004-03-31 2005-10-20 Saika Technological Institute Foundation Stationary phase extraction cartridge
JP2008020275A (en) * 2006-07-12 2008-01-31 Hitachi Koki Co Ltd Automatic solid-phase extractor
JP2011089924A (en) * 2009-10-23 2011-05-06 Hitachi High-Technologies Corp Drug analysis device
JP2011095069A (en) * 2009-10-29 2011-05-12 Hitachi High-Technologies Corp Clinical examination system, clinical examination method, and equipment for pretreatment

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105452871A (en) * 2013-08-23 2016-03-30 株式会社日立高新技术 Analysis device and analysis method
CN104266885A (en) * 2014-07-25 2015-01-07 安徽省一一通信息科技有限公司 Sample automatic-treatment system
CN105784455A (en) * 2016-05-16 2016-07-20 张起香 Extraction structure and liquid pretreatment device
US10150065B2 (en) 2016-05-16 2018-12-11 Tianjin Anbang Jinahe Technology Co., Ltd. Extraction structure, extraction module, and liquid pretreatment device
CN113960224A (en) * 2021-09-26 2022-01-21 裕菁科技(上海)有限公司 Additive applied to liquid-liquid extraction pretreatment of biological sample and extraction method

Also Published As

Publication number Publication date
JP2013096733A (en) 2013-05-20

Similar Documents

Publication Publication Date Title
WO2013062084A1 (en) Analysis device and analysis method
Moein et al. Bioanalytical method development and validation: Critical concepts and strategies
US8926903B2 (en) Pretreatment apparatus and mass spectrometer equipped with the same apparatus
JP5433580B2 (en) Sample injection system
EP2543994B1 (en) Analysis device
Molina-Díaz et al. Solid-phase spectroscopy from the point of view of green analytical chemistry
US8865418B2 (en) Immunoanalytical method and system using mass spectrometry technology
McPolin An introduction to HPLC for pharmaceutical analysis
CN105102977A (en) C peptide detection by mass spectrometry
Cordero et al. Development of a new system for the speciation of chromium in natural waters and human urine samples by combining ion exchange and ETA-AAS
Kubáň et al. Flow/sequential injection sample treatment coupled to capillary electrophoresis. A review
Gundersen et al. Quantitative high-performance liquid chromatographic determination of retinoids in human serum using on-line solid-phase extraction and column switching Determination of 9-cis-retinoic acid, 13-cis-retinoic acid, all-trans-retinoic acid, 4-oxo-all-trans-retinoic acid and 4-oxo-13-cis-retinoic acid
CN111208252B (en) Quantitative detection method of tretinoin in human plasma
JP2007512515A5 (en)
Liu et al. Best practices in biological sample preparation for LC‐MS bioanalysis
US9885732B2 (en) Analysis device and analysis method
CN105334282B (en) Co-detecting method for environmental estrogens in surface water body
JPH03205559A (en) Chromatographic analysis of biosample and liquid chromatograph device
JP7520824B2 (en) Pretreatment method for automatic analyzer
Kupiec et al. High-performance liquid chromatography
EP0429082A2 (en) Method for analysis of catecholamine
Zhou et al. A fully automatic HPLC–CAD–DAD method coupled with ASE and online SPE for simultaneous determination of seven antibiotics in bio-matrices
KR20210117268A (en) High-Speed Sample Workflow for LC-MS-Based HBA1C Instrumentation
Mujewar et al. A review on bioanalytical method development and various validation stages involved in method development using RP-HPLC
He et al. A Cartridge Structure Facilitates Clinical Mass Spectrometry Pretreatment and Can be Integrated Into a High‐Throughput Instrument

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12843681

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12843681

Country of ref document: EP

Kind code of ref document: A1